BK40196 is an inhibitor of c-Abl, which makes it a strategic therapeutic agent for idiopathic PD due to the widely established effects of c-Abl on alpha-synuclein [17,18] degradation via autophagy [19,20]. This evidence concerns the gene ABL1 and Parkinson disease.